References
- Falsey AR, Walsh EE, Hayden FG. Rhinovirus and coronavirus infection-associated hospitalizations among older adults. J Infect Dis. 2002;185(9):1338–1341.
- de Haan CAM, Masters PS, Shen X, et al. The group-specific murine coronavirus genes are not essential, but their deletion, by reverse genetics, is attenuating in the natural host. Virology. 2002 Apr 25;296(1):177–189.
- Rota PA, Oberste MS, Monroe SS, et al. Characterization of a novel coronavirus associated with severe acute respiratory syndrome. Science. 2003;300(5624):1394.
- Drosten C, Günther S, Preiser W, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1967–1976.
- Junhui Z, Thomas B, Erhei D, et al. Real-time polymerase chain reaction for detecting SARS coronavirus, Beijing, 2003. Emerg Infect Dis J. 2004;10(2):300.
- Guan Y, Zheng BJ, He YQ, et al. Isolation and characterization of viruses related to the SARS coronavirus from animals in Southern China. Science. 2003;302(5643):276.
- Cascella M, Rajnik M, Cuomo A, et al. Features, Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC.; 2020.
- Sahin AR, Erdogan A, Agaoglu PM, et al. 2019 novel coronavirus (COVID-19) outbreak: a review of the current literature. EJMO. 2020;4(1):1–7.
- Zheng J. SARS-CoV-2: an emerging coronavirus that causes a global threat [Review]. Int J Biol Sci. 2020;16(10):1678–1685.
- Omrani AS, Al-Tawfiq JA, Memish ZA. Middle East respiratory syndrome coronavirus (MERS-CoV): animal to human interaction. Pathog Glob Health. 2015 Nov 17;109(8):354–362.
- Sun J, He W-T, Wang L, et al. COVID-19: epidemiology, evolution, and cross-disciplinary perspectives. Trends Mol Med. 2020 May 01;26(5):483–495.
- Zhang T, Wu Q, Zhang Z. Probable pangolin origin of SARS-CoV-2 associated with the COVID-19 outbreak. Curr Biol. 2020 Apr 06;30(7):1346–1351.e2.
- Furuya T, Macnaughton TB, La Monica N, et al. Natural evolution of coronavirus defective-interfering RNA involves RNA recombination. Virology. 1993 May 01;194(1):408–413.
- Andersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of SARS-CoV-2. Nat Med. 2020 Apr 01;26(4):450–452.
- Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–733.
- Luk HKH, Li X, Fung J, et al. Molecular epidemiology, evolution and phylogeny of SARS coronavirus. Infect Genet Evol. 2019 Jul 01;71:21–30.
- Walls AC, Park Y-J, Tortorici MA, et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell. 2020 Apr 16;181(2):281–292.e6.
- Yadav PD, Potdar VA, Choudhary ML, et al. Full-genome sequences of the first two SARS-CoV-2 viruses from India. Indian J Med Res. 2020 Feb & Mar;151(2 & 3):200–209.
- Perlman S, Netland J. Coronaviruses post-SARS: update on replication and pathogenesis. Nature Rev Microbiol. 2009 Jun 01;7(6):439–450.
- Ou X, Liu Y, Lei X, et al. Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. Nat Commun. 2020 Mar 27;11(1):1620.
- Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020 Apr 16;181(2):271–280.e8.
- Yang P, Wang X. COVID-19: a new challenge for human beings. Cell Mol Immunol. 2020 May;17(5):555–557.
- Zhang SF, Tuo JL, Huang XB, et al. Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in Guangzhou. PLoS One. 2018;13(1):e0191789.
- Zhang Y-Z, Holmes EC, Genomic A. Perspective on the origin and emergence of SARS-CoV-2. Cell. 2020 Apr 16;181(2):223–227.
- Wu A, Peng Y, Huang B, et al. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe. 2020 Mar 11;27(3):325–328.
- Shereen MA, Khan S, Kazmi A, et al. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. J Adv Res. 2020 Jul;24:91–98.
- Wang N, Shang J, Jiang S, et al. Subunit vaccines against emerging pathogenic human coronaviruses [Review]. Front Microbiol. 2020 Feb 28;11:298.
- Wu Y-C, Chen C-S, Chan Y-J. The outbreak of COVID-19: an overview. J Chin Med Assoc. 2020;83(3):217–220.
- Bchetnia M, Girard C, Duchaine C, et al. The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A review of the current global status. J Infect Public Health. 2020 Aug 04;20:30591–30598.
- Wikipedia. Template:COVID-19 pandemic data. Wikipedia; 2020 [updated 2020 Jul 15; cited 2020 Aug 26]. Available from: https://en.wikipedia.org/wiki/Template:COVID-19_pandemic_data
- Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020 May 5;172(9):577–582.
- Estrada E. Fractional diffusion on the human proteome as an alternative to the multi-organ damage of SARS-CoV-2. Chaos Interdiscip J Nonlinear Sci. 2020 Aug 01; 30(8):081104.
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 Feb 15;395(10223):497–506.
- WHO. Q&A on coronaviruses (COVID-19). World Health Orgazation; 2020 [updated 2020 Apr 17 2020; cited 2020 May 25]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/question-and-answers-hub/q-a-detail/q-a-coronaviruses
- Schiffrin EL, Flack JM, Ito S, et al. Hypertension and COVID-19. Am J Hypertens. 2020;33(5):373–374.
- Vicenzi M, Di Cosola R, Ruscica M, et al. The liaison between respiratory failure and high blood pressure: evidence from COVID-19 patients. Eur Respir J. 2020;56(1):2001157.
- Singhal TA. Review of coronavirus disease-2019 (COVID-19). Indian J Pediatr. 2020 Apr 01;87(4):281–286.
- Xu X-W, Wu -X-X, Jiang X-G, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020;368:m606.
- Lakshmi Priyadarsini S, Suresh M. Factors influencing the epidemiological characteristics of pandemic COVID 19: A TISM approach. Int J Healthc Manage. 2020 Apr 02;13(2):89–98.
- Lei J, Kusov Y, Hilgenfeld R. Nsp3 of coronaviruses: structures and functions of a large multi-domain protein. Antiviral Res. 2018 Jan;149:58–74.
- Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nature Rev Microbiol. 2019 Mar 01;17(3):181–192.
- Organization WH. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance, 13 March 2020. World Health Organization; 2020 [updated 2020 Mar 13; cited 2020 Aug 26]. Available from: https://apps.who.int/iris/handle/10665/331446
- Organization WH. Estimating mortality from COVID-19. World Health Organization; 2020 [updated 2020 Aug 4; cited 2020 Aug 26]. Available from: https://www.who.int/news-room/commentaries/detail/estimating-mortality-from-covid–19
- WHO. Coronavirus disease (COVID-2019) situation reports. World Health Organization; 2020 [updated 2020 May 25; cited 2020 May 25]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
- Suyash Desai NS Why WHO must be partly ‘blamed’ for coronavirus global pandemic. The Quint’s Newsletter; 2020 [cited 2020 Aug 25]. Available from: https://www.thequint.com/voices/opinion/coronavirus-covid-19-china-deception-lies-world-health-organization
- Altug B. WHO criticized for ‘contradictory’ COVID-19 statements. Anadolu Agency; 2020 [updated 2020 Jul 7; cited 2020 Aug 25]. Available from: https://www.aa.com.tr/en/europe/who-criticized-for-contradictory-covid-19-statements/1902436
- Funck-Brentano C, Salem J-E. RETRACTED: chloroquine or hydroxychloroquine for COVID-19: why might they be hazardous? Lancet. 2020. DOI:10.1016/S0140-6736(20)31174-0
- Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507–513.
- Arabi YM, Al-Omari A, Mandourah Y, et al. Critically ill patients with the middle east respiratory syndrome: a multicenter retrospective cohort study. Crit Care Med. 2017 Oct;45(10):1683–1695.
- Lai CC, Liu YH, Wang CY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. J Microbiol Immunol Infect. 2020 Mar 4;53:404–412.
- WHO. Global surveillance for COVID-19 caused by human infection with COVID-19 virus: interim guidance. World Health Organization; 2020 [updated 2020 Apr 20 25; cited 2020 May 25]. Available from: https://www.who.int/publications-detail/global-surveillance-for-covid-19-caused-by-human-infection-with-covid-19-virus-interim-guidance
- Athrady A. COVID-19: indian Railways converts 2,500 coaches into isolation wards 6 April 2020. Decan Herald; 2020 [cited 2020 May 25]. Available from: https://www.deccanherald.com/national/covid-19-indian-railways-converts-2500-coaches-into-isolation-wards-821958.html
- Zhu W, Wang Y, Xiao K, et al. Establishing and managing a temporary coronavirus disease 2019 specialty hospital in Wuhan, China. Anesthesiology. 2020 Jun;132(6):1339–1345.
- Lardieri A. New york will create more temporary hospitals to handle surge in COVID-19 patients. U.S. News and World Report; 2020 [updated 2020 Mar 27; cited 2020 Apr 19]. Available from: https://www.usnews.com/news/health-news/articles/2020-03-27/new-york-is-establishing-more-temporary-hospitals-to-handle-surge-of-coronavirus-patient
- Marci F. Coronavirus: italy’s worst-hit region builds new hospital in 10 days. Independent; 2020 [updated 2020 Mar 31; cited cited 2020 Apr 19]. Available from: https://www.independent.co.uk/news/world/europe/coroanvirus-italy-hospital-milan-lombardy-cases-deaths-a9438761.html
- Guardian T. Prince Charles to open NHS Nightingale to treat Covid-19 patients. The Guardian; 2020 [updated 2020 Apr 3; cited 2020 Apr 19]. Available from: https://www.theguardian.com/world/2020/apr/03/prince-charles-to-open-nhs-nightingale-to-treat-covid-19-patients
- Phua J, Weng L, Ling L, et al. Intensive care management of coronavirus disease 2019 (COVID-19): challenges and recommendations. Lancet Respir Med. 2020 May 01;8(5):506–517.
- Wong J, Goh QY, Tan Z, et al. Preparing for a COVID-19 pandemic: a review of operating room outbreak response measures in a large tertiary hospital in Singapore. Can J Anaesth. 2020 Jun;67(6):732–745.
- Remuzzi A, Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020 Apr 11;395(10231):1225–1228.
- Heymann D, Shindo N. WHO scientific and technical advisory group for infectious hazards. COVID-19: what is next for public health. Lancet. 2020;395(10224):542–545.
- Ali I, Alharbi OML. COVID-19: disease, management, treatment, and social impact. Sci Total Environ. 2020 Aug 1;728:138861.
- Liu Y, Li J, Feng Y. Critical care response to a hospital outbreak of the 2019-nCoV infection in Shenzhen, China. Crit Care. 2020 Feb 19;24(1):56.
- Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9;71:732–739.
- Chen C, Zhang XR, Ju ZY, et al. Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies. Zhonghua Shao Shang Za Zhi. 2020 Mar 1;36:E005.
- Shen C, Wang Z, Zhao F, et al. Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA. 2020 Mar 27;323:1582.
- Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther. 2020;14(1):58–60.
- Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of Covid-19 - preliminary report. N Engl J Med. 2020 May 22. DOI:10.1056/NEJMoa2007764
- Maoujoud O, Asserraji M, Ahid S, et al. Anakinra for patients with COVID-19. Lancet Rheumatol. 2020 Jul;2(7):e383.
- Horby P, Lim WS, Emberson JR, et al. Dexamethasone in hospitalized patients with Covid-19 — preliminary report. N Engl J Med. 2020;oa2021436.
- Lurie N, Saville M, Hatchett R, et al. Developing Covid-19 vaccines at pandemic speed. N Engl J Med. 2020 May 21;382(21):1969–1973.
- Du L, Jiang S. Middle East respiratory syndrome: current status and future prospects for vaccine development. Expert Opin Biol Ther. 2015 Nov 02;15(11):1647–1651.
- Padron-Regalado E. Vaccines for SARS-CoV-2: lessons from other coronavirus strains. Infect Dis Ther. 2020 Apr 23;9(2):255–274.
- Agrawal AS, Tao X, Algaissi A, et al. Immunization with inactivated Middle East respiratory syndrome coronavirus vaccine leads to lung immunopathology on challenge with live virus. Hum Vaccin Immunother. 2016 Sep;12(9):2351–2356.
- Yong CY, Ong HK, Yeap SK, et al. Recent advances in the vaccine development against middle east respiratory syndrome-coronavirus. Front Microbiol. 2019;10:1781.
- Le Thanh T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. 2020 May;19(5):305–306.
- Gouglas D, Le Thanh T, Henderson K, et al. Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study. Lancet Glob Health. 2018 Dec;6(12):e1386–e1396.
- Organization WH. Coronavirus disease (COVID-19) advice for the public. World Health Organization; 2020 [cited 2020 Aug 25]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public?gclid=EAIaIQobChMI6PLQ1-Gx6wIVkiQrCh3J3g81EAAYASAAEgJR3PD_BwE
- Wang Y, Zhang D, Du G, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 May 16;395(10236):1569–1578.
- van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med. 2020 Apr 16;382(16):1564–1567.
- Arabi YM, Murthy S, Webb S. Correction to: COVID-19: a novel coronavirus and a novel challenge for critical care. Intensive Care Med. 2020 May;46(5):1087–1088.
- WHO. Infection prevention and control during health care when novel coronavirus (nCoV) infection is suspected. World Health Organization; 2020 [updated 2020 Mar 19; cited 2020 May 25]. Available from: https://www.who.int/publications-detail/infection-prevention-and-control-during-health-care-when-novel-coronavirus-(ncov)-infection-is-suspected–20200125
- Garrett L. COVID-19: the medium is the message. Lancet. 2020 Mar 21;395(10228):942–943.
- Carter LJ, Garner LV, Smoot JW, et al. Assay techniques and test development for COVID-19 diagnosis. ACS Cent Sci. 2020 Apr 30;6:591–605.
- CDC. Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19. Centers for Diseases Control and Prevention; 2020 [updated 2020 Apr 14; cited 2020 Apr 16]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelines-clinical-specimens.html
- Fang Y, Zhang H, Xie J, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology. 2020;296.
- Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2020;296.
- Tahamtan A, Ardebili A. Real-time RT-PCR in COVID-19 detection: issues affecting the results. Expert Rev Mol Diagn. 2020 May;20(5):453–454.
- Chan JF-W, Yip CC-Y, To KK-W, et al. Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated <em> In Vitro</em> and with clinical specimens. J Clin Microbiol. 2020;58(5):e00310–20.
- Administration FaD. Xpert® Xpress SARS-CoV-2. Food and Drug Administrator; 2020 [cited 2020 Aug 26]. Available from: https://www.fda.gov/media/136314/download
- FIND. SARS-COV-2 diagnostic pipeline. FIND; 2020 cited 2020 Apr 16. Available from: https://www.finddx.org/covid-19/pipeline/
- ICMR. Performance evaluation of commercial kits for real time PCR for COVID-19 by ICMR identified validation centres; 2020 [updated 2020 May 25]. Available from: https://www.icmr.gov.in/ckitevaluation.html
- Lei J, Li J, Li X, et al. CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 2020;295(1):18.
- Webb WR, Brant WE, Major NM. Fundamentals of Body CT E-Book. Philadelphia (PA): Elsevier Health Sciences; 2019.
- Li Y, Xia L. Coronavirus disease 2019 (COVID-19): role of chest ct in diagnosis and management. AJR Am J Roentgenol. 2020 Jun;214(6):1280–1286.
- Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020 Feb 13;30:3306–3309.
- Lee HK, Lee BH, Seok SH, et al. Production of specific antibodies against SARS-coronavirus nucleocapsid protein without cross reactivity with human coronaviruses 229E and OC43. J Vet Sci. 2010 Jun;11(2):165–167.
- Wan Zhuoyue ZX, Xinge Y. IFA in testing specific antibody of SARS coronavirus. South China J Preventive Med. 2003;29(3):36–37.
- MedScape. FDA approves test that can detect coronavirus in minutes. MedScape; 2020 [updated 2020 Mar 28; cited 2020 Apr 16]. Available from: https://www.medscape.com/viewarticle/927717
- Li Z, Yi Y, Luo X, et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol. 2020;1518–1524.
- BioSystem O BioMedomics COVID-19 IgM/IgG rapid test. Oxford BioSystem; 2020 [cited 2020 Apr 16]. Available from: https://www.oxfordbiosystems.com/COVID-19-Rapid-test
- Shmerling R. Which test is best for COVID-19?. Harvard Health Publishing; 2020 [updated Aug 17; cited 2020 Aug 26]. Available from: https://www.health.harvard.edu/blog/which-test-is-best-for-covid–19–2020081020734
- Kai Kupferschmidt JC. WHO launches global megatrial of the four most promising coronavirus treatments; 2020 [updated 2020 Mar 22; cited 2020 Apr 16]. Available from: https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments#
- Chakravarti A, Upadhyay S, Bharara T, et al. Current understanding, knowledge gaps and a perspective on the future of COVID-19 Infections: A systematic review [Review Article: covid-19 Series]. Indian J Med Microbiol. 2020 Jan 1;38(1):1–8.
- Jin Z, Smith LK, Rajwanshi VK, et al. The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5ʹ-triphosphate towards influenza A virus polymerase. PLoS One. 2013;8(7):e68347.
- Pascua PNQ, Marathe BM, Vogel P, et al. Optimizing T-705 (favipiravir) treatment of severe influenza B virus infection in the immunocompromised mouse model. J Antimicrob Chemother. 2019 May 1;74(5):1333–1341.
- Furuta Y, Gowen BB, Takahashi K, et al. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antiviral Res. 2013 Nov;100(2):446–454.
- Caroline AL, Powell DS, Bethel LM, et al. Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever. PLoS Negl Trop Dis. 2014 Apr;8(4):e2790.
- Furuta Y, Takahashi K, Shiraki K, et al. T-705 (favipiravir) and related compounds: novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res. 2009 Jun;82(3):95–102.
- USCC. China’s biotechnology development: the role of us and other foreign engagement. U.S.-China Economic And Security Review Commission; 2020 [updated 2019 Feb 14; cited 2019 May 25]. Available from: https://www.uscc.gov/sites/default/files/Research/US-China%20Biotech%20Report.pdf
- Singh AK, Singh A, Shaikh A, et al. Chloroquine and hydroxychloroquine in the treatment of COVID-19 with or without diabetes: A systematic search and a narrative review with a special reference to India and other developing countries. Diabetes Metab Syndr. 2020 May - Jun;14(3):241–246.
- Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22;2(1):69.
- Al-Horani RA, Kar S, Aliter KF. Potential anti-COVID-19 therapeutics that block the early stage of the viral life cycle: structures, mechanisms, and clinical trials. Int J Mol Sci. 2020;21(15):5224.
- Simmons G, Bertram S, Glowacka I, et al. Different host cell proteases activate the SARS-coronavirus spike-protein for cell-cell and virus-cell fusion. Virology. 2011 May 10;413(2):265–274.
- Devaux CA, Rolain JM, Colson P, et al. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents. 2020 Mar 12;55(5):105938.
- Owens B. Excitement around hydroxychloroquine for treating COVID-19 causes challenges for rheumatology. Lancet Rheumatol. 2020;2(5):e257.
- Tang W, Cao Z, Han M, et al. Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial. BMJ. 2020 May 14;369:m1849.
- Mahase E. Covid-19: hydroxychloroquine was ineffective as postexposure prophylaxis, study finds. BMJ. 2020 Jun 5;369:m2242.
- Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med. 2020 Aug 6;383(6):517–525.
- Peter Horby ML No clinical benefit from use of hydroxychloroquine in hospitalised patients with COVID-19: Recovery; 2020 [updated 2020 Jun 5; cited 2020 Aug 25]. Available from: https://www.recoverytrial.net/news/statement-from-the%20chief-investigators-of-the-randomised-evaluation-of-covid-19-therapy-recovery-trial-on%20hydroxychloroquine-5-june-2020-no-clinical-benefit-from-use-of-hydroxychloroquine-in%20hospitalised-patients-with-covid–19
- Amirian ES, Levy JK. Current knowledge about the antivirals remdesivir (GS-5734) and GS-441524 as therapeutic options for coronaviruses. One Health. 2020 Jun;9:100128.
- Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017 Jun 28;9(396):eaal3653.
- Grein J, Ohmagari N, Shin D, et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med. 2020 Apr 10;382:2327–2336.
- Reina J. Remdesivir, the antiviral hope against SARS-CoV-2. Rev Esp Quimioter. 2020 Apr 1;33(3):176–179.
- Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269–271.
- Goldman JD, Lye DCB, Hui DS, et al. Remdesivir for 5 or 10 days in patients with severe Covid-19. N Engl J Med. 2020 May 27;oa2015301.
- Agency EM. First COVID-19 treatment recommended for EU authorisation. European Medicines Agency; 2020 [cited 2020 Aug 26]. Available from: https://www.ema.europa.eu/en/news/first-covid-19-treatment-recommended-eu-authorisation
- Administration FaD. Frequently asked questions on the emergency use authorization for remdesivir for certain hospitalized COVID-19 patients. U. S. Food and Drug Administration; 2020 [updated 2020 Jul 30; cited 2020 Aug 25]. Available from: https://www.fda.gov/media/137574/download
- Lehar J, Krueger AS, Avery W, et al. Synergistic drug combinations tend to improve therapeutically relevant selectivity. Nat Biotechnol. 2009 Jul;27(7):659–666.
- Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20;56:105949.
- Retallack H, Di Lullo E, Arias C, et al. Zika virus cell tropism in the developing human brain and inhibition by azithromycin. Proc Natl Acad Sci U S A. 2016 Dec 13;113(50):14408–14413.
- Madrid PB, Panchal RG, Warren TK, et al. Evaluation of ebola virus inhibitors for drug repurposing. ACS Infect Dis. 2015 Jul 10;1(7):317–326.
- Tran DH, Sugamata R, Hirose T, et al. Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A(H1N1)pdm09 virus infection by interfering with virus internalization process. J Antibiot (Tokyo). 2019 Oct;72(10):759–768.
- Fantini J, Chahinian H, Yahi N. Synergistic antiviral effect of hydroxychloroquine and azithromycin in combination against SARS-CoV-2: what molecular dynamics studies of virus-host interactions reveal. Int J Antimicrob Agents. 2020 May 13;56:106020.
- Zimmer K. Why some COVID-19 cases are worse than others. The Scientist; 2020 [updated 2020 Feb 24; cited 2020 Apr 15]. Available from: https://www.the-scientist.com/news-opinion/why-some-covid-19-cases-are-worse-than-others–67160
- Anderson C, Sheppard D, Dorval AD. Parkinsonism and subthalamic deep brain stimulation dysregulate behavioral motivation in a rodent model. Brain Res. 2020 Jun 1;1736:146776.
- Tang F, Li R, Xue J, et al. Azithromycin attenuates acute radiation-induced lung injury in mice. Oncol Lett. 2017 Nov;14(5):5211–5220.
- Olsen M, Cook SE, Huang V, et al. Perspectives: potential therapeutic options for SARS-CoV-2 patients based on feline infectious peritonitis strategies: central nervous system invasion and drug coverage. Int J Antimicrob Agents. 2020 Apr 3;55:105964.
- Liu J, Cao R, Xu M, et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discov. 2020;6:16.
- Cavalcanti AB, Zampieri FG, Rosa RG, et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N Engl J Med. 2020 Jul 23. DOI:10.1056/NEJMoa2019014
- Baden LR, Rubin EJ. Covid-19 - the search for effective therapy. N Engl J Med. 2020 May 7;382(19):1851–1852.
- Zehbe I, Richard C, Lee KF, et al. Lopinavir shows greater specificity than zinc finger ejecting compounds as a potential treatment for human papillomavirus-related lesions. Antiviral Res. 2011 Aug;91(2):161–166.
- Batman G, Oliver AW, Zehbe I, et al. Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cells. Antivir Ther. 2011;16(4):515–525.
- Cao B, Wang Y, Wen D, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020 May 7;382(19):1787–1799.
- FDA. KALETRA®. Food and Drug Administrative; 2000 [cited 2020 Apr 15]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021226s018lbl.pdf
- Cooper CL, van Heeswijk RP, Gallicano K, et al. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis. 2003 Jun 15;36(12):1585–1592.
- Harrison C. Coronavirus puts drug repurposing on the fast track. Nat Biotechnol. 2020 Apr;38(4):379–381.
- Kai Kupferschmidt JC. WHO launches global megatrial of the four most promising coronavirus treatments. Science; 2020 [updated 2020 Mar 22; cited 2020 Jun 6]. Available from: https://www.sciencemag.org/news/2020/03/who-launches-global-megatrial-four-most-promising-coronavirus-treatments#
- Medicine USNLo. Lopinavir/ritonavir, ribavirin and IFN-beta combination for nCoV treatment. Clinicaltrials.gov; 2020 [cited 2020 Aug 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT04276688
- Frieman M, Heise M, Baric R. SARS coronavirus and innate immunity. Virus Res. 2008 Apr;133(1):101–112.
- Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222.
- Hung IF, Lung KC, Tso EY, et al. Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020 May 30;395(10238):1695–1704.
- Arabi YM, Alothman A, Balkhy HH, et al. Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-beta1b (MIRACLE trial): study protocol for a randomized controlled trial. Trials. 2018 Jan 30;19(1):81.
- Schrezenmeier E, Dorner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nat Rev Rheumatol. 2020 Mar;16(3):155–166.
- Cooper RG, Magwere T. Chloroquine has not disappeared. Afr Health Sci. 2007 Sep;7(3):185–186.
- Rolain JM, Colson P, Raoult D. Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century. Int J Antimicrob Agents. 2007 Oct;30(4):297–308.
- Yang N, Shen HM. Targeting the endocytic pathway and autophagy process as a novel therapeutic strategy in COVID-19. Int J Biol Sci. 2020;16(10):1724–1731.
- Xue J, Moyer A, Peng B, et al. Chloroquine is a zinc ionophore. PLoS One. 2014;9(10):e109180.
- Read SA, Obeid S, Ahlenstiel C, et al. The role of zinc in antiviral immunity. Adv Nutr. 2019 Jul 1;10(4):696–710.
- Kaushik N, Subramani C, Anang S, et al. Zinc salts block hepatitis e virus replication by inhibiting the activity of viral RNA-dependent RNA polymerase. J Virol. 2017 Nov 1;91(21):e00754–17.
- Te Velthuis AJ, van den Worm SH, Sims AC, et al. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. PLoS Pathog. 2010 Nov 4;6(11):e1001176.
- Derwand R, Scholz M. Does zinc supplementation enhance the clinical efficacy of chloroquine/hydroxychloroquine to win today’s battle against COVID-19? Med Hypotheses. 2020 Sep 01;142:109815.
- Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490–9496.
- Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. J Antimicrob Chemother. 2005 Nov;56(5):919–922.
- Hopkins JS. Drugmaker takeda is working on coronavirus drug. The Wall Street Journal; 2020 [updated 2020 Mar 4; cited 2020 May 25]. Available from: https://www.wsj.com/articles/drugmaker-takeda-is-working-on-coronavirus-drug–11583301660
- Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020 Apr 1;130(4):1545–1548.
- Tomar D. India’s first Covid-19 patient treated with plasma therapy recovers. India Today; 2020 [updated 2020 Apr 26; cited 2020 May 25]. Available from: https://www.indiatoday.in/india/story/india-s-first-to-be-treated-with-plasma-therapy-covid-19-patient-recovers-1671339-2020-04–26
- Chakraborty R First Covid-19 patient to receive plasma therapy in Maharashtra dies. Hindustan Times; 2020 [updated 2020 Apr 30; cited 2020 May 25]. Available from: https://www.hindustantimes.com/india-news/first-covid-19-patient-to-receive-plasma-therapy-in-maharashtra-dies/story-Gxa8zmEzbF8UEKsKlQ19KN.html
- Now T. Convalescent plasma therapy: ICMR gets approval for trials to test effectiveness in COVID-19 treatment. Times Now; 2020 [updated 2020 May 9; cited 2020 May 25]. Available from: https://www.timesnownews.com/health/article/convalescent-plasma-therapy-icmr-gets-approval-for-trials-to-test-effectiveness-in-covid-19-treatment/589357
- Chen Z, John Wherry E. T cell responses in patients with COVID-19. Nat Rev Immunol. 2020 Jul 29;529:529–536.
- Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970–10975.
- Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents. 2020 Jun;55(6):105982.
- De Rossi N, Scarpazza C, Filippini C, et al. Early use of low dose tocilizumab in patients with COVID-19: A retrospective cohort study with a complete follow-up. EClinicalMedicine. 2020 Jul 17;25:100459.
- Bermejo I, Ren S, Simpson E, et al. Sarilumab for previously-treated moderate or severe rheumatoid arthritis: an evidence review group perspective of a NICE single technology appraisal. Pharmacoeconomics. 2018 Dec;36(12):1427–1437.
- Lamb YN, Deeks ED. Sarilumab: a review in moderate to severe rheumatoid arthritis. Drugs. 2018 Jun;78(9):929–940.
- Medicine USNLo. Evaluation of the efficacy and safety of sarilumab in hospitalized patients with COVID-19. Clinicaltrials.gov; 2020 [updated 2020 Aug 11; cited Aug 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT04315298
- Sanofi. Sanofi and regeneron provide update on Kevzara® (sarilumab) Phase 3 U.S. trial in COVID-19 patients. Sanofi; 2020 [updated 2020 Jul 2; cited 2020 Aug 29]. Available from: https://www.sanofi.com/en/media-room/press-releases/2020/2020-07-02-22-30–00
- Dimopoulos G, de Mast Q, Markou N, et al. Favorable anakinra responses in severe Covid-19 patients with secondary hemophagocytic lymphohistiocytosis. Cell Host Microbe. 2020 Jul 8;28(1):117–123 e1.
- Fu B, Xu X, Wei H. Why tocilizumab could be an effective treatment for severe COVID-19? J Transl Med. 2020 Apr 14;18(1):164.
- Xiu S, Dick A, Ju H, et al. Inhibitors of SARS-CoV-2 entry: current and future opportunities. J Med Chem. 2020 Jun 15. DOI:10.1021/acs.jmedchem.0c00502
- Ho TY, Wu SL, Chen JC, et al. Design and biological activities of novel inhibitory peptides for SARS-CoV spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res. 2006 Feb;69(2):70–76.
- Adedeji AO, Severson W, Jonsson C, et al. Novel inhibitors of severe acute respiratory syndrome coronavirus entry that act by three distinct mechanisms. J Virol. 2013 Jul;87(14):8017–8028.
- Prabakaran P, Gan J, Feng Y, et al. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem. 2006 Jun 9;281(23):15829–15836.
- Li J, Zhan P, Liu X. Targeting the entry step of SARS-CoV-2: a promising therapeutic approach. Signal Transduct Target Ther. 2020 Jun 17;5(1):98.
- Azimi A. TMPRSS2 inhibitors, bromhexine, aprotinin, camostat and nafamostat as potential treatments for COVID-19. Frenxiv. 2020;1–20.
- McGonagle D, Sharif K, O’Regan A, et al. Interleukin-6 use in COVID-19 pneumonia related macrophage activation syndrome. Autoimmun Rev. 2020;19:102537.
- Wan S, Yi Q, Fan S, et al. Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). MedRxiv. 2020:832.
- Barnes PJ. How corticosteroids control inflammation: quintiles prize lecture 2005. Br J Pharmacol. 2006 Jun;148(3):245–254.
- Sibila O, Agusti C, Torres A. Corticosteroids in severe pneumonia. Eur Respir J. 2008 Aug;32(2):259–264.
- Auyeung TW, Lee JS, Lai WK, et al. The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study. J Infect. 2005 Aug;51(2):98–102.
- Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with Middle East respiratory syndrome. Am J Respir Crit Care Med. 2018 Mar 15;197(6):757–767.
- Organization WH. Corticosteroids for COVID-19. World Health Organization; 2020 [updated 2020 Sep 2; cited 2020 Sep 23]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-Corticosteroids-2020.1
- Health NIo. COVID-19 treatment guidelines. National Institute of Health; 2020 [updated Aug 27; cited 2020 Sep 23]. Available from: https://www.covid19treatmentguidelines.nih.gov/immune-based-therapy/immunomodulators/corticosteroids/
- Mubarak A, Alturaiki W, Hemida MG. Middle East respiratory syndrome coronavirus (MERS-CoV): infection, immunological response, and vaccine development. J Immunol Res. 2019;2019:6491738.
- Graham RL, Donaldson EF, Baric RS. A decade after SARS: strategies for controlling emerging coronaviruses. Nature Rev Microbiol. 2013 Dec 01;11(12):836–848.
- Pulendran B, Ahmed R. Immunological mechanisms of vaccination. Nat Immunol. 2011 Jun;12(6):509–517.
- MilkenInstitute. COVID-19 treatment and vaccine tracker. Milken Institute; 2020 [cited 2020 Aug 25]. Available from: https://milkeninstitute.org/sites/default/files/2020-03/Covid19-Tracker-3-36-20-FINAL.pdf
- NIH. NIH clinical trial of investigational vaccine for COVID-19 begins. National Institute of Health; 2020 [updated 2020 Mar 16]. Available from: https://www.nih.gov/news-events/news-releases/nih-clinical-trial-investigational-vaccine-covid-19-begins
- Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med. 2020;oa2022483.
- Patel NV. Moderna’s latest vaccine results are promising—but it’s still too early. MIT Technology Review; 2020 [updated 2020 May 18; cited 2020 May 26]. Available from: https://www.technologyreview.com/2020/05/18/1001834/moderna-coronavirus-vaccine-phase-i-interim-clinical-trial-results/
- Corbett KS, Flynn B, Foulds KE, et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N Engl J Med. 2020;383:1544–1555.
- NLM. Phase I clinical trial of a COVID-19 vaccine in 18–60 healthy adults (CTCOVID-19). U. S. National Library of Medicine; 2020 [updated May 19 2020; cited 2020 May 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT04313127
- Arena CT University of Oxford starts enrolment for Covid-19 vaccine trial. Clinical Trials Arena; 2020 [updated 2020 Mar 30; cited 2020 May 25]. Available from: https://www.clinicaltrialsarena.com/news/oxford-university-covid-19-vaccine-trial/
- Carlson R. INO-4800 DNA coronavirus vaccine; 2020 [updated 2020 May 20; cited 2020 May 25]. Available from: https://www.precisionvaccinations.com/vaccines/ino-4800-dna-coronavirus-vaccine
- V S. Clinical Trail; 2020 [cited 2020 Aug 26]. Available from: https://sputnikvaccine.com/about-vaccine/clinical-trials/
- WHO. Middle East respiratory syndrome coronavirus (MERS-CoV): World Health Organisation; 2019 [updated 11 March 2019;27 March 2020]. Available from: https://www.who.int/en/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-(mers-cov)
- WHO. Acute respiratory syndrome in China: World Health Organization; 2003 [updated 11 February 2003;25 May 2020]. Available from: https://www.who.int/csr/don/2003_02_11/en/
- Zhang C, Zheng W, Huang X, et al. Protein Structure and Sequence Reanalysis of 2019-nCoV Genome Refutes Snakes as Its Intermediate Host and the Unique Similarity between Its Spike Protein Insertions and HIV-1. Journal of Proteome Research. 2020/04/03;19(4):1351–1360.
- Chan-Yeung M, Xu RH. SARS: epidemiology. Respirology. 2003 Nov;8 Suppl:S9-14. WHO. SARS (Severe Acute Respiratory Syndrome): World Health Organization; 2002 [25 May 2020]. Available from: https://www.who.int/ith/diseases/sars/en/
- WHO. Coronavirus disease (COVID-19) pandemic: World Health Organization; 2020 [updated 25 May 2020;25 May 2020]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019
- WHO. Summary table of available protocols in this document: World Health Organization; 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/whoinhouseassays.pdf?sfvrsn=de3a76aa_2
- WHO. WHO PCR protocol: World Health Organization; 2020 [2 March 2020]. Available from: https://www.who.int/docs/default-source/coronaviruse/real-time-rt-pcr-assays-for-the-detection-of-sars-cov-2-institut-pasteur-paris.pdf?sfvrsn=3662fcb6_2
- CDC. Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-PCR Primers and Probes: Centers for Disease Control and Prevention 2020 [8 January 2020]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-panel-primer-probes.html
- WHO. Diagnostic detection of 2019-nCoV by real-time RT-PCR: World Health Organization; 2020 [updated 17 January 2020;16 April 2020]. Available from: Diagnostic detection of Wuhan coronavirus 2019 by real-time RT-PCR – Charité, Berlin Germany
- AccuBioTech. Accu-Tell® COVID-19 IgG/IgM Rapid Test Cassette: AccuBioTech; 2020 [16 April 2020]. Available from: https://www.accubiotech.com/product-covid-19-igg-igm-rapid-test-cassette-(whole-blood-serum-plasma).html
- Biosensors S. STANDARD Q COVID-19 Ag: SD Biosensors; 2020 [16 April 2020]. Available from: http://sdbiosensor.com/xe/product?act%3D%26mid%3DContactus%26vid%3D%26_filter%3Dsearch%26act%3D%26vid%3D%26mid%3Dproduct%26search_target%3Dtitle%26search_keyword%3DCOVID%2B19
- Biosensors S. STANDARD Q COVID-19 IgM/IgG Duo test kit SD Biosensors; 2020 [16 April 2020]. Available from: http://sdbiosensor.com/xe/product%3Fact%3D%26mid%3DContactus%26vid%3D%26_filter%3Dsearch%26act%3D%26vid%3D%26mid%3Dproduct%26search_target%3Dtitle%26search_keyword%3DCOVID%2B19
- Cepheid. Xpert® Xpress SARS-CoV-2 has received FDA Emergency Use Authorization: Cepheid; 2020 [16 April 2020]. Available from: https://www.cepheid.com/coronavirus
- Cellex. Cellex qSARS-COV-2 IgG/IgM Rapid Test: Cellex; 2020 [16 April 2020]. Available from: https://cellex.us/ShowNews/%3F34-1.html
- Genetics E. Edinburgh Genetics COVID-19 Immunoassay Testing Kits: Edinburgh Genetics; 2020 [16 April 2020]. Available from: https://eggenetics.com/covid-19-colloidal-gold